GLUCAGON-LIKE PEPTIDE-1-BASED THERAPIES IN CARDIOVASCULAR DISEASE: EVIDENCE, MECHANISMS, AND EMERGING CLINICAL APPLICATIONS

Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico 'G. Rodolico-San Marco', University of Catania

GLP-1 receptor agonists have shown significant cardiovascular benefits in patients with type 2 diabetes and established cardiovascular disease, reducing major adverse cardiovascular events. The review discusses the mechanisms behind these benefits, including metabolic, inflammatory, and vascular effects. It also highlights the potential of dual GIP and GLP-1 receptor agonists and the implications for treating obesity and heart failure with preserved ejection fraction. The document summarizes current evidence and clinical recommendations for the use of GLP-1 therapies in various cardiometabolic contexts.